The advantages of HPV ctDNA detection compared to "classical" ctDNA (e.g KRAS/TP53 mutation) are: (i) The presence of HPV in >90% of cases and the low cost of tumor HPV genotyping (while testing for tumor genomic alterations can be negative and is more expensive). This evidence concerns the gene KRAS and neoplasm.